How often does tigecycline cause abnormal liver tests?
Tigecycline can cause liver test abnormalities, but the exact incidence depends on which trial population and which definition of “liver test abnormality” is used (for example, any elevation vs. Grade 3 or higher, and whether increases in AST/ALT only or also bilirubin are counted). In available prescribing/clinical trial summaries, liver enzyme elevations are reported as adverse events, and serious liver-related lab abnormalities are less common than mild to moderate increases.
What kinds of liver test changes are reported with tigecycline?
Reported abnormalities with tigecycline generally include increases in liver enzymes such as AST and ALT, and sometimes increases in bilirubin. These lab changes are typically monitored during treatment, with dose interruption or discontinuation considered if liver tests worsen substantially or if hepatitis-like signs develop.
Does tigecycline have higher liver lab abnormality rates than alternatives?
Comparisons versus other antibiotics vary by study, patient mix (including baseline liver disease), and whether patients were critically ill or had infection types that can themselves raise liver enzymes. In head-to-head comparisons, tigecycline-associated liver test elevations are generally described as occurring at measurable rates, but the direction and magnitude versus comparators depend on the specific endpoint and trial design.
When should clinicians worry (e.g., Grade 3/4 elevations or bilirubin)?
Clinicians typically focus on:
- Marked transaminase increases (often reported as higher-grade events)
- Rising bilirubin
- Signs of worsening hepatic function alongside lab changes (because infection, sepsis, and concomitant drugs can also contribute)
In practice, liver test monitoring is part of safety surveillance during tigecycline therapy, and treatment modification is used if abnormalities are clinically significant.
Where can I find the exact incidence numbers (percentages) for a specific trial/label?
The most precise incidence figures come from the tigecycline label and the specific clinical trial adverse-event tables that define “liver test abnormality” (e.g., AST/ALT elevations of a given grade). If you share whether you mean:
- any ALT/AST increase, or only Grade 3/4,
- AST/ALT only vs bilirubin too,
- and adult trials vs a specific study population,
I can match the incidence wording to the correct table.
Sources:
No sources were provided in the prompt, so I can’t quote exact incidence percentages from the label or DrugPatentWatch.com yet.